32,282 Shares in Zimmer Biomet Holdings, Inc. $ZBH Purchased by Rakuten Investment Management Inc.

Rakuten Investment Management Inc. purchased a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 32,282 shares of the medical equipment provider’s stock, valued at approximately $2,945,000.

Several other institutional investors also recently bought and sold shares of the business. DV Equities LLC acquired a new position in shares of Zimmer Biomet during the 4th quarter worth approximately $25,000. Tacita Capital Inc acquired a new stake in Zimmer Biomet in the 2nd quarter valued at $26,000. Ancora Advisors LLC acquired a new stake in Zimmer Biomet in the 2nd quarter valued at $29,000. Monetary Solutions Ltd purchased a new stake in Zimmer Biomet in the 4th quarter worth $30,000. Finally, Gen Wealth Partners Inc purchased a new stake in Zimmer Biomet in the 4th quarter worth $31,000. 88.89% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have issued reports on ZBH. Weiss Ratings raised shares of Zimmer Biomet from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, August 4th. Canaccord Genuity Group boosted their target price on shares of Zimmer Biomet from $83.00 to $100.00 and gave the stock a “hold” rating in a research note on Monday, August 10th. Sanford C. Bernstein upped their price target on shares of Zimmer Biomet from $91.00 to $93.00 and gave the stock a “market perform” rating in a research report on Thursday, August 6th. Royal Bank Of Canada raised their price target on shares of Zimmer Biomet from $101.00 to $110.00 and gave the company an “outperform” rating in a research note on Thursday, August 6th. Finally, BMO Capital Markets reiterated a “market perform” rating and issued a $96.00 price objective on shares of Zimmer Biomet in a report on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Zimmer Biomet has an average rating of “Hold” and a consensus price target of $104.42.

Zimmer Biomet Stock Up 0.2%

NYSE ZBH opened at $101.10 on Monday. The business has a fifty day moving average price of $93.88 and a 200 day moving average price of $91.46. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.94 and a current ratio of 1.69. The company has a market cap of $19.28 billion, a P/E ratio of 24.60, a P/E/G ratio of 2.74 and a beta of 0.45. Zimmer Biomet Holdings, Inc. has a one year low of $79.12 and a one year high of $106.88.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.01 by $0.06. The company had revenue of $2.18 billion for the quarter, compared to analysts’ expectations of $2.13 billion. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The firm’s quarterly revenue was up 4.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.07 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.54 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend is Wednesday, September 30th. Zimmer Biomet’s dividend payout ratio is currently 23.36%.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.